Home » Topics » BioWorld Science

BioWorld Science
RSS

H. Lee Moffitt Cancer Center and Research Institute presents YAP1/POU5F1 interaction inhibitors

Oct. 8, 2019

Biogen patents OGA inhibitors

Oct. 8, 2019

Hawaii Biotech divulges compounds for anthrax

Oct. 8, 2019

Inhaled AZD-8154 demonstrates superior pharmacokinetics over intravenous administration

Oct. 8, 2019

NKTR-358 begins new phase Ib studies in psoriasis and atopic dermatitis

Oct. 8, 2019

First cohort subject dosed in phase I study of SCD inhibitor YTX-7739

Oct. 8, 2019

Enrollment underway in phase I/II study of CTNS-RD-04 stem cell gene therapy for cystinosis

Oct. 8, 2019

C-75 improves survival of mice with sepsis through blocking TLR/MYD88 signaling in neutrophils

Oct. 8, 2019

Phase I results for DNA vaccine MVI-118 in patients with metastatic prostate cancer

Oct. 8, 2019

rSIFN-co demonstrates antitumor activity in phase I study in advanced solid tumors

Oct. 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...